NCT02222454View on ClinicalTrials.gov

Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2015

Conditions
Pressure Ulcers Stage IIPressure Ulcers Stage III
Interventions
DEVICE

KLOX BioPhotonic System

KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.

Trial Locations (4)

T2N 4Z6

Calgary Center for Clinical Research, Calgary

K7L 3N6

Queen's University, Kingston

N6C 2R5

Lawton Health Research Institute, London

J7Z 5T3

St-Jerome Medical Research Inc., Saint-Jérôme

Sponsors
All Listed Sponsors
lead

KLOX Technologies Inc.

INDUSTRY